Clinical profile and outcome of large-vessel giant cell arteritis in Japanese patients: A single-centre retrospective cohort study

Mod Rheumatol. 2023 Jan 3;33(1):175-181. doi: 10.1093/mr/roac013.

Abstract

Objectives: Recent advances in imaging revealed that giant cell arteritis (GCA) is frequently associated with large vessel involvement (LVI), but they may also contribute to earlier diagnosis and treatment of LV-GCA. We aimed to compare the clinical characteristics of GCA with or without LVI and evaluate its association with clinical outcomes.

Method: We retrospectively reviewed the medical records of 36 patients with GCA in Kyoto University Hospital.

Results: Eighteen patients each were assigned to the LVI(+) and LVI(-) groups. Five-year survival rates in the LVI(+) group were better than in the LVI(-) group (p = .034), while five-year relapse-free survival rates were similar between the groups (p = .75). The LVI(+) group required lower doses of glucocorticoid at month 6 (p = .036). Disease activity evaluated with the Birmingham Vasculitis Activity Score at disease onset was higher in the LVI(-) group (p = .014), and the Vasculitis Damage Index score examined at the last visit was higher in the LVI(-) group (p = .011).

Conclusion: GCA without LVI had more active disease, severer vascular damage, and worse survival, possibly because of ophthalmic complications and their greater glucocorticoid requirement. Our results revisit the impact of cranial manifestations on disease severity and morbidity.

Keywords: Diagnostic imaging; giant cell arteritis; large vessel involvement; ophthalmic manifestations.

MeSH terms

  • East Asian People
  • Giant Cell Arteritis* / complications
  • Giant Cell Arteritis* / diagnosis
  • Giant Cell Arteritis* / drug therapy
  • Glucocorticoids / therapeutic use
  • Humans
  • Retrospective Studies

Substances

  • Glucocorticoids